Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01862770 · ClinicalTrials.gov registry record
Effect of Lung Cancer Diagnoses on Family Behaviors
A clinical trial of Lung Cancer and Blood Relatives of Patient w/Lung Cancer, sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- 507
- Enrollment target
- 2
- Study locations
NCT01862770 is a study of Lung Cancer and Blood Relatives of Patient w/Lung Cancer that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 507 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (46% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01862770, a study of Lung Cancer and Blood Relatives of Patient w/Lung Cancer, has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- 507 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: \- A health event can be a powerful motivator for abrupt behavior changes. For instance, many people who smoke stop after having a heart attack or being diagnosed with cancer. A relative s health event may have a similar effect. For instance, smokers may try to quit after learning that a parent or sibling has lung cancer. Researchers want to study relatives of people with lung cancer to see how the relative s diagnosis affects a person s willingness to quit smoking or have genetic testing. Objectives: \- To study the impact of a relative s lung cancer diagnosis on a person s approach to genetic testing and smoking cessation services. Eligibility: \- Current smokers between 18 and 55 years of age who are close blood relatives of people being treated for lung cancer. Design: * Participants will be recruited through telephone surveys. Participants will log on to a password-protected website. The site has two educational sessions and three surveys to complete. * Participants will also be offered free genetic testing. The test will see whether they have a gene that can reduce the effectiveness of some cancer treatment drugs. Those who agree to the test will collect a cheek swab sample at home and send the sample in for testing. They will receive the test results through the website. * The surveys will ask about risk perceptions and emotional responses to the relative s diagnosis. They will also ask about smoking history, motivation to quit, and reactions to information about smoking and genetic risk. * All participants will be able to receive free smoking cessation services. * Six months after completing the surveys, participants will have a follow-up phone call. The call will ask whether participants used the smoking cessation services.
Conditions Studied
Study Locations (2)
Florida
- Moffitt Cancer Center - Tampa
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2012-12-18 |
| Est. Completion | 2016-02-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01862770
The ClinicalTrials.gov registry entry for NCT01862770 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 507 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (46% lower). The listed sponsor is National Human Genome Research Institute (NHGRI), which has 185 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01862770 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01862770 about?
NCT01862770 is a clinical study titled "Effect of Lung Cancer Diagnoses on Family Behaviors". Background: \- A health event can be a powerful motivator for abrupt behavior changes. For instance, many people who smoke stop after having a heart attack or being diagnosed with cancer. A relative s health event may have a similar effect. For instance, smokers may try to quit after learning that ...
What is the current status of trial NCT01862770?
This trial is currently completed. The enrollment target is 507 participants. The study started on 2012-12-18. Estimated completion is 2016-02-25.
What conditions does trial NCT01862770 study?
This clinical trial studies the following conditions: Lung Cancer, Blood Relatives of Patient w/Lung Cancer, Cigarette Smokers.
Who is sponsoring clinical trial NCT01862770?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01862770 being conducted?
This trial has 2 study locations across Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.